These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33188828)

  • 1. Synthetic high-density lipoproteins delivering liver X receptor agonist prevent atherogenesis by enhancing reverse cholesterol transport.
    Yuan W; Yu B; Yu M; Kuai R; Morin EE; Wang H; Hu D; Zhang J; Moon JJ; Chen YE; Guo Y; Schwendeman A
    J Control Release; 2021 Jan; 329():361-371. PubMed ID: 33188828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression.
    Guo Y; Yuan W; Yu B; Kuai R; Hu W; Morin EE; Garcia-Barrio MT; Zhang J; Moon JJ; Schwendeman A; Eugene Chen Y
    EBioMedicine; 2018 Feb; 28():225-233. PubMed ID: 29361501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanodisc delivery of liver X receptor agonist for the treatment of diabetic nephropathy.
    He H; Halseth TA; Mei L; Shen C; Liu L; Schwendeman A
    J Control Release; 2022 Aug; 348():1016-1027. PubMed ID: 35750132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergetic Effect of rHDL and LXR Agonist on Reduction of Atherosclerosis in Mice.
    Morin EE; Guo Y; He H; Yuan W; Souery WN; Fawaz MV; Chen YE; Schwendeman A
    Front Pharmacol; 2020; 11():513031. PubMed ID: 33390931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
    Yan W; Zhang T; Cheng J; Zhou X; Qu X; Hu H
    Pharmacology; 2010; 86(5-6):306-12. PubMed ID: 21071998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Synthetic High Density Lipoproteins Modification with Polyethylene Glycol on Pharmacokinetics and Pharmacodynamics.
    Li D; Fawaz MV; Morin EE; Ming R; Sviridov D; Tang J; Ackermann R; Olsen K; Remaley AT; Schwendeman A
    Mol Pharm; 2018 Jan; 15(1):83-96. PubMed ID: 29141139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phospholipid Component Defines Pharmacokinetic and Pharmacodynamic Properties of Synthetic High-Density Lipoproteins.
    Fawaz MV; Kim SY; Li D; Ming R; Xia Z; Olsen K; Pogozheva ID; Tesmer JJG; Schwendeman A
    J Pharmacol Exp Ther; 2020 Feb; 372(2):193-204. PubMed ID: 31776208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice.
    Peng D; Hiipakka RA; Dai Q; Guo J; Reardon CA; Getz GS; Liao S
    J Pharmacol Exp Ther; 2008 Nov; 327(2):332-42. PubMed ID: 18723776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic LXR agonist inhibits the development of atherosclerosis in New Zealand White rabbits.
    Honzumi S; Shima A; Hiroshima A; Koieyama T; Terasaka N
    Biochim Biophys Acta; 2011 Dec; 1811(12):1136-45. PubMed ID: 21875689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
    Chen Y; Duan Y; Yang X; Sun L; Liu M; Wang Q; Ma X; Zhang W; Li X; Hu W; Miao RQ; Xiang R; Hajjar DP; Han J
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of notch enhances the anti-atherosclerotic effects of LXR agonists while reducing fatty liver development in ApoE-deficient mice.
    Hao Y; Wang X; Zhang F; Wang M; Wang Y; Wang H; Du Y; Wang T; Fu F; Gao Z; Zhang L
    Toxicol Appl Pharmacol; 2020 Nov; 406():115211. PubMed ID: 32853627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophage-independent regulation of reverse cholesterol transport by liver X receptors.
    Breevoort SR; Angdisen J; Schulman IG
    Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1650-60. PubMed ID: 24947527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis.
    Hsieh J; Koseki M; Molusky MM; Yakushiji E; Ichi I; Westerterp M; Iqbal J; Chan RB; Abramowicz S; Tascau L; Takiguchi S; Yamashita S; Welch CL; Di Paolo G; Hussain MM; Lefkowitch JH; Rader DJ; Tall AR
    Nature; 2016 Jul; 535(7611):303-7. PubMed ID: 27383786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia.
    Kratzer A; Buchebner M; Pfeifer T; Becker TM; Uray G; Miyazaki M; Miyazaki-Anzai S; Ebner B; Chandak PG; Kadam RS; Calayir E; Rathke N; Ahammer H; Radovic B; Trauner M; Hoefler G; Kompella UB; Fauler G; Levi M; Levak-Frank S; Kostner GM; Kratky D
    J Lipid Res; 2009 Feb; 50(2):312-26. PubMed ID: 18812595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infusions of Large Synthetic HDL Containing Trimeric apoA-I Stabilize Atherosclerotic Plaques in Hypercholesterolemic Rabbits.
    Parolini C; Adorni MP; Busnelli M; Manzini S; Cipollari E; Favari E; Lorenzon P; Ganzetti GS; Fingerle J; Bernini F; Chiesa G
    Can J Cardiol; 2019 Oct; 35(10):1400-1408. PubMed ID: 31495683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in Mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo.
    Beyer TP; Schmidt RJ; Foxworthy P; Zhang Y; Dai J; Bensch WR; Kauffman RF; Gao H; Ryan TP; Jiang XC; Karathanasis SK; Eacho PI; Cao G
    J Pharmacol Exp Ther; 2004 Jun; 309(3):861-8. PubMed ID: 14960661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of T0901317 on ATP-binding cassette transporter A1 and Niemann-Pick type C1 in apoE-/- mice.
    Dai XY; Ou X; Hao XR; Cao DL; Tang YL; Hu YW; Li XX; Tang CK
    J Cardiovasc Pharmacol; 2008 May; 51(5):467-75. PubMed ID: 18437096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of liver X receptor decreases atherosclerosis in Ldlr⁻/⁻ mice in the absence of ATP-binding cassette transporters A1 and G1 in myeloid cells.
    Kappus MS; Murphy AJ; Abramowicz S; Ntonga V; Welch CL; Tall AR; Westerterp M
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):279-84. PubMed ID: 24311381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver X receptor activation promotes polyunsaturated fatty acid synthesis in macrophages: relevance in the context of atherosclerosis.
    Varin A; Thomas C; Ishibashi M; Ménégaut L; Gautier T; Trousson A; Bergas V; de Barros JP; Narce M; Lobaccaro JM; Lagrost L; Masson D
    Arterioscler Thromb Vasc Biol; 2015 Jun; 35(6):1357-65. PubMed ID: 25838428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological LXR activation reduces presence of SR-B1 in liver membranes contributing to LXR-mediated induction of HDL-cholesterol.
    Grefhorst A; Oosterveer MH; Brufau G; Boesjes M; Kuipers F; Groen AK
    Atherosclerosis; 2012 Jun; 222(2):382-9. PubMed ID: 22481067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.